Darapladib, a potential therapeutic agent specifically targeting LpPLA2 activity, is currently under investigation as a treatment administered after acute coronary syndromes and for stable coronary disease [5], [6]. This evidence concerns the gene PLA2G7 and coronary artery disorder.